Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Other Non-Current Assets (2019 - 2025)

Keros Therapeutics (KROS) has disclosed Other Non-Current Assets for 7 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Assets rose 3.5% year-over-year to $1.4 million, compared with a TTM value of $1.4 million through Dec 2025, up 3.5%, and an annual FY2025 reading of $1.4 million, up 3.5% over the prior year.
  • Other Non-Current Assets was $1.4 million for Q4 2025 at Keros Therapeutics, roughly flat from $1.4 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $1.4 million in Q3 2024 and bottomed at $115000.0 in Q1 2021.
  • Average Other Non-Current Assets over 5 years is $1.2 million, with a median of $1.3 million recorded in 2021.
  • The sharpest move saw Other Non-Current Assets soared 1227.0% in 2021, then dropped 9.57% in 2023.
  • Year by year, Other Non-Current Assets stood at $1.3 million in 2021, then changed by 0.0% to $1.3 million in 2022, then fell by 9.57% to $1.2 million in 2023, then increased by 16.67% to $1.4 million in 2024, then increased by 3.5% to $1.4 million in 2025.
  • Business Quant data shows Other Non-Current Assets for KROS at $1.4 million in Q4 2025, $1.4 million in Q3 2025, and $1.4 million in Q2 2025.